NCT04381364 (HALT) is a Phase 2 clinical trial of Ciclesonide Inhalation Aerosol in Covid-19, sponsored by Ola Blennow, MD, PhD.

Who is sponsoring NCT04381364?

NCT04381364 is sponsored by Ola Blennow, MD, PhD.

What drugs are being tested in NCT04381364?

Interventions in NCT04381364: Ciclesonide Inhalation Aerosol.

What condition does NCT04381364 study?

NCT04381364 studies Covid-19, Pneumonia, Viral, Sars-CoV2.

Is NCT04381364 still recruiting?

NCT04381364 is currently status unknown. Last updated 2 February 2022.

Last reviewed 2022-02-02 · How we verify

NCT04381364: HALT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)

Status unknown Phase 2 Last updated 2 February 2022

What this trial tests

Phase 2 trial testing Ciclesonide Inhalation Aerosol in Covid-19 in 98 participants. Status unknown.

Timeline

29 May 2020

Primary endpoint
1 August 2021

31 January 2022

Quick facts

Lead sponsor	Ola Blennow, MD, PhD
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	98
Start date	29 May 2020
Primary completion	1 August 2021
Estimated completion	31 January 2022
Sites	11 locations across Sweden

Drugs / interventions tested

Ciclesonide Inhalation Aerosol — full drug profile →

Conditions studied

Covid-19 — all drugs for Covid-19 →
Pneumonia, Viral — all drugs for Pneumonia, Viral →
Sars-CoV2 — all drugs for Sars-CoV2 →

Sponsor

Ola Blennow, MD, PhD — full company profile →

Who can join

18 and older, any sex, with Covid-19 or Pneumonia, Viral. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Randomized open label clinical trial carried out at study centers in Sweden, including Karolinska University Hospital, S:t Göran Hospital, Danderyd Hospital and Västmanlands Hospital. Patients with COVID-19 who are hospitalized with oxygen therapy are eligible for inclusion. Subjects are randomized to 14 days of inhalation with ciclesonide 360 µg twice daily or to standard of care. Primary outcome is duration of received supplemental oxygen therapy. Key secondary outcome is a composite outcome of death and received invasive mechanical ventilation within 30 days.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Covid-19

Currently open trials in the same condition.

NCT05943743 — Hiccups and Obstacles Of E-Learning Among Medical Sudents · recruiting
NCT04466683 — Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia · Phase 2 · active not recruiting
NCT04433364 — COPE - COVID-19 in Pregnancy and Early Childhood · active not recruiting
NCT04568148 — COVID-19 Biorepository · active not recruiting
NCT04360538 — Long Term Outcomes of Patients With COVID-19 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04381364 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ola Blennow, MD, PhD
Last refreshed: 2 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04381364.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing